Power3 Medical Products Inc. is a leader in bio-medical research, particularly cancer biomarkers, pathways, and mechanisms of disease, through the development of diagnostic tests and drug targets. The company’s patent-pending technologies are used to develop screening and diagnostic tests for the early detection and prognosis of cancers and neurodegenerative diseases such as Parkinson’s disease.

Power3 Medical announced today that results for the early stage diagnosis from clinical validation trials of the company’s NuroProPD test for Parkinson’s disease are better than expected. The NuroProPD test was developed to help clinicians distinguish patients with Parkinson’s disease from “normal” individuals and patients with other neurological disorders.

The NurpProPD test, developed by Power3, utilizes a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability that a patient has Parkinson’s disease. The latest results from the completion of the first phase of clinical validation trials showed a sensitivity of 93.3% for detection of mild, moderate, and severe Parkinson’s disease. The sensitivity for early-stage Parkinson’s patients was 100% and the specificity of the test of normal individuals was 96.2%.

Helen R. Park, CEO of Power3, commenting on the success of the company’s NuroProPD product said, “The progress of the clinical validation achieved to date affirms our belief that NuroProPD will help physicians make earlier diagnoses and recommend appropriate follow-up and treatment options for their patients”.

Let us hear your thoughts below: